SIRFLOX clinical trial Selective Internal Radiation Therapy SIR-Spheres treatment liver metastases liver tumour colorectal cancer

SIRFLOX.com

Selective Internal Radiation Therapy using SIR-Spheres

Skip to main menu and site information
Sirtex.com website
Current path: Home

For patients

SIRFLOX is an international research study designed to evaluate a new treatment option for patients with colorectal cancer that has undergone metastatic spread to the liver. The study completed recruitment in April 2013 and results will be available in mid 2015.

About the SIRFLOX study

The study is designed to evaluate whether FOLFOX6m chemotherapy in combination with Selective Internal Radiation Therapy is more effective than chemotherapy alone. This study represents the first time that these treatments have been assessed together as part of a randomised controlled study and as a first-line therapy (i.e. in patients who have not previously received chemotherapy for their liver metastases).

For patients

The SIRFLOX study is no longer recruiting patients. If you have or have had colorectal cancer that has spread to the liver and your cancer cannot be treated with surgery at this time, you may talk with your doctor about further treatment options.

About Selective Internal Radiation Therapy with SIR-Spheres Y-90 resin microspheres

Selective Internal Radiation Therapy (SIRT) is a form of treatment that has been designed to selectively deliver radiation to the cancer within the liver.

SIRT involves injecting very small radioactive particles known as SIR-Spheres Y-90 resin microspheres into the blood supply of the liver. The administration of SIR-Spheres Y-90 resin microspheres is a form of radiotherapy and is designed to destroy cancer in the liver. The SIR-Spheres Y-90 resin microspheres are administered via a small tube known as a catheter. This catheter is inserted into an artery in the patient's groin and then guided by the doctor to a position near the cancer in the liver. The SIR-Spheres Y-90 resin microspheres are then introduced directly into the blood supply of the liver following which they lodge in the small blood vessels of the liver tumours where they deliver their radiation directly to the tumours. In this clinical research study SIRT was given on the 3rd or 4th day of the first 'cycle' of chemotherapy.

More information on the treatment and patient support can be found in the patient section of www.sirtex.com 

W005-EUA-0315

About the SIRFLOX study

The SIRFLOX study is an international research study designed to evaluate a new treatment option for patients with colorectal cancer that has undergone metastatic spread to the liver.

Back to top


SIRFLOX clinical trial Selective Internal Radiation Therapy SIR-Spheres treatment liver metastases liver tumour colorectal cancer